Adlai Nortye Ltd. (NASDAQ:ANL) Short Interest Up 49.0% in August

Adlai Nortye Ltd. (NASDAQ:ANL) was the recipient of a significant growth in short interest in August. As of August 31st, there was short interest totalling 15,500 shares, a growth of 49.0% from the August 15th total of 10,400 shares. Based on an average daily volume of 9,000 shares, the short-interest ratio is currently 1.7 days.

Wall Street Analyst Weigh In

ANL has been the subject of a number of recent research reports. HC Wainwright initiated coverage on shares of Adlai Nortye in a report on Wednesday, September 4th. They issued a “buy” rating and a $9.00 price objective for the company. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Adlai Nortye in a research report on Thursday, June 20th.

Hedge Funds Weigh In On Adlai Nortye

A hedge fund recently raised its stake in Adlai Nortye stock. Cantor Fitzgerald L. P. grew its position in Adlai Nortye Ltd. (NASDAQ:ANL) by 128.2% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 40,310 shares of the company’s stock after buying an additional 22,644 shares during the period. Cantor Fitzgerald L. P. owned approximately 0.11% of Adlai Nortye worth $362,000 at the end of the most recent quarter. Institutional investors and hedge funds own 35.21% of the company’s stock.

Adlai Nortye Stock Up 16.8 %

ANL opened at $2.29 on Monday. The company has a fifty day moving average price of $3.05 and a two-hundred day moving average price of $6.82. Adlai Nortye has a 52 week low of $1.90 and a 52 week high of $19.30.

About Adlai Nortye

Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas.